Affiliations: [a] Department of Beijing National Biochip Research Center Sub-Center in Ningxia, The General Hospital of Ningxia Medical University, Yinchuan 750001, Ningxia, China | [b] Department of Hepatobiliary Surgery, The General Hospital of Ningxia Medical University, Yinchuan 750001, Ningxia, China | [c] Department of Biobank, The General Hospital of Ningxia Medical University, Yinchuan 750001, Ningxia, China | [d] Department of Gastroenterology, The General Hospital of Ningxia Medical University, Yinchuan 750001, Ningxia, China | [e] Minimally Invasive Treatment Center, Fudan University Shanghai Cancer Center, Shanghai 200032, China | [f] Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
Correspondence:
[*]
Corresponding author: Yong-Qiang Hua, Minimally Invasive Treatment Center, Fudan University Shanghai Cancer Center, 270 Dong An Road, Shanghai 200032, China. Tel.: +86 21 64175590 83633; Fax: +86 21 64049440; E-mail: bu72chesiliaoji@163.com.
Note: [1] These authors contributed equally to the work.
Abstract: BACKGROUND: Recent study revealed that abnormal long noncoding RNAs (lncRNAs) expression are association with chemotherapy resistance of pancreatic ductal adenocarcinoma (PDAC). OBJECTIVE: The present study was aimed to investigate the effects of lncRNA AB209630 expression for gemcitabine resistance in PDAC cells. METHODS: In the study, increased expression of lncRNA AB209630 could suppress cell proliferation and cell colony formation ability in gemcitabine resistance cells of PDAC. Furthermore, western blot results demonstrated that upregulation of lncRNA AB209630 suppressed the PI3K/AKT signaling pathway in gemcitabine resistance cells. Besides, we found that lncRNA AB209630 expression was dramatically downregulated in PDAC tissues compared to adjacent normal tissues. Lower PDAC expression predicted a poor prognosis in PDAC patients. CONCLUSIONS: Thus, these results indicated that lncRNA AB209630 may be a potential target of PDAC.
